Accueil   Diary - News   All news Kigabeq® launch in Germany

Kigabeq® launch in Germany



ORPHELIA Pharma and DESITIN GmbH announce the launch of Kigabeq® in Germany


Paris/Lyon and Hamburg, July 16, 2019 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric drugs in the fields of oncology and neurology, announces today that it has entered into a license and distribution agreement with the epilepsy specialist Desitin GmbH to market Kigabeq® in Germany.


Read the press release


By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree